Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

5C27

Crystal structure of SYK in complex with compound 2

Summary for 5C27
Entry DOI10.2210/pdb5c27/pdb
Related5C26
DescriptorTyrosine-protein kinase SYK, GLU-VAL-TYR-GLU-SER, 3-{8-[(3,4-dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}-N-[4-(methylcarbamoyl)phenyl]benzamide, ... (5 entities in total)
Functional Keywordsspleen tyrosine kinase, inhibitor, transferase-inhibitor complex, transferase/inhibitor
Biological sourceHomo sapiens (Human)
More
Cellular locationCell membrane : P43405
Total number of polymer chains2
Total formula weight36281.20
Authors
Han, S.,Chang, J. (deposition date: 2015-06-15, release date: 2015-10-07, Last modification date: 2024-11-13)
Primary citationLovering, F.,Aevazelis, C.,Chang, J.,Dehnhardt, C.,Fitz, L.,Han, S.,Janz, K.,Lee, J.,Kaila, N.,McDonald, J.,Moore, W.,Moretto, A.,Papaioannou, N.,Richard, D.,Ryan, M.S.,Wan, Z.K.,Thorarensen, A.
Imidazotriazines: Spleen Tyrosine Kinase (Syk) Inhibitors Identified by Free-Energy Perturbation (FEP).
Chemmedchem, 11:217-233, 2016
Cited by
PubMed Abstract: There has been significant interest in spleen tyrosine kinase (Syk) owing to its role in a number of disease states, including autoimmunity, inflammation, and cancer. Ongoing therapeutic programs have resulted in several compounds that are now in clinical use. Herein we report our optimization of the imidazopyrazine core scaffold of Syk inhibitors through the use of empirical and computational approaches. Free-energy perturbation (FEP) methods with MCPRO+ were undertaken to calculate the relative binding free energies for several alternate scaffolds. FEP was first applied retrospectively to determine if there is any predictive value; this resulted in 12 of 13 transformations being predicted in a directionally correct manner. FEP was then applied in a prospective manner to evaluate 17 potential targets, resulting in the realization of imidazotriazine 17 (3-(4-(3,4-dimethoxyphenylamino)imidazo[1,2-f][1,2,4]triazin-2-yl)benzamide), which shows a tenfold improvement in activity relative to the parent compound and no increase in atom count. Optimization of 17 led to compounds with nanomolar cellular activity.
PubMed: 26381330
DOI: 10.1002/cmdc.201500333
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.15 Å)
Structure validation

238268

数据于2025-07-02公开中

PDB statisticsPDBj update infoContact PDBjnumon